A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer

Administered By

Awarded By

Contributors

Start/End

  • September 5, 2017 - September 1, 2020